The Trip of a Lifetime
DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A Mark your calendar – DOSED
July 6, 2022
DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A Mark your calendar – DOSED
Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US
Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic
Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder Study Initiated Following
UNITy: World’s first study of how DMT-induced brain changes predict improved wellbeing University College London
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions
Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder Clearmind aims
Awakn Life Sciences Completes World’s First Ketamine Study For A Range Of Behavioral Addictions Collectively,
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption Pre-clinical trial demonstrated
Clearmind Announces Pre-IND Meeting Date with FDA Clearmind aims to initiate clinical trials with CMND-100
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination
If you’ve been wanting to try psychedelic therapy legally, now’s your chance! Johns Hopkins is
Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample A
Ibogaine blocks some of the rewarding effects of alcohol in rodent model of addictive behavior
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study Clinical trial programs advance
Clearmind Medicine Announces Positive Results on CMND-100 trials wo pre-clinical trials based on MEAI exhibited
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study Company rapidly prepares
Clearmind Medicine to Host a “Psychedelics for Alcoholism” Event for Investors on February 23 Market
Universal Ibogaine and Osoyoos Indian Band sign MOU to battle opioid crisis Universal Ibogaine (IBO)
Entheon Biomedical Announces the Approval of DMT Clinical Trial Entheon Biomedical (ENBI) received approval for a
Fish on acid? Microdosing zebrafish with LSD shows its potential benefits for humans New research suggests
Universal Ibogaine Commences Development Plan At Kelburn In Preparation For Ibogaine Treatments And Provides Update